Top

High Blood Pressure & Cardiovascular Prevention

Published in:

01-03-2018 | Original Article

Role of Acetyl Salicylic Acid in Controlling the DOCA-Salt Induced Hypertension in Rats by Stimulating the Synthesis of r-Cortexin in the Kidney

Authors: Uttam Kumar Maji, Pradipta Jana, Mitali Chatterjee, Sanmay Karmakar, Arup Saha, Tamal Kanti Ghosh

Published in: High Blood Pressure & Cardiovascular Prevention | Issue 1/2018

Abstract

Introduction

Hypertension is a metabolic disease which is caused by vasoconstriction and that results into elevated blood pressure. A chronic hypertensive condition affects and even damages to various systems in the body. Presence of renal cortexin (r-cortexin), an antihypertensive protein, which is released from the kidney cortex controls the blood pressure. The effect of r-cortexin was mediated through nitric oxide (NO), a universal vasodilating agent.

Aim

In our study, acetyl salicylic acid (aspirin), a well-known activator of the endothelial nitric oxide synthase (eNOS) induced r-cortexin synthesis.

Methods

The hypertensive rat model was prepared by injecting deoxy corticosterone acetate (DOCA). Synthesis of r-cortexin was measured by the anti-r-cortexin antibody which was raised in adult white Wister albino rat model. NO level was determined by using methemoglobin method and later confirmed by chemiluminescence method. Change in blood pressure was determined indirectly by using NIBP monitoring system.

Results

Aspirin increased the r-cortexin expression from 64.36 ± 12.6 nM to 216.7 ± 21.31 nM in DOCA induced hypertensive rats. The mechanism was proved with the findings of increased level of NO from 0.4 to 1.9 µM. The DOCA induced blood pressure was also decreased from 139.39 ± 7.36 mm of Hg to 116.57 ± 6.89 mm of Hg in case of systolic blood pressure and in case of diastolic pressure from 110.41 ± 7 mm of Hg to 86.4 ± 2.76 mm of Hg that are quite approximate.

Conclusion

So, from this study it has been found that aspirin induces the r-cortexin synthesis in kidney cortex through the activation of eNOS in DOCA induced hypertensive rats.

Nolan MT, Russell DJ, Marwick TH. Long-term risk of heart failure and myocardial dysfunction after thoracic radiotherapy: a systematic review. Can J Cardiol. 2016;32(7):908–20.CrossRefPubMed

Georgiopoulos G, Tsioufis C, Tsiachris D, Dimitriadis K, Liatakis I, Kalos T, et al. Metabolic syndrome predicts independently from its components adverse events in essential hypertensive subjects. J Hypertens. 2015;33(Suppl 1):e91.CrossRefPubMed

Mrozikiewicz-Rakowska B, Maroszek P, Nehring P, Sobczyk-Kopciol A, Krzyzewska M, Kaszuba AM, et al. Genetic and environmental predictors of chronic kidney disease in patients with type 2 diabetes and diabetic foot ulcer: a pilot study. J Physiol Pharmacol. 2015;66(5):751–61.PubMed

Ojji DB, Libhaber E, Atherton JJ, Abdullahi B, Nwankwo A, Sliwa K. Risk-factor profile and comorbidities in 2398 patients with newly diagnosed hypertension from the abuja heart study. Medicine (Baltimore). 2015;94(39):e1660.CrossRefPubMedPubMedCentral

Moreira MC, Pinto IS, Mourão AA, Fajemiroye JO, Colombari E, Reis ÂA, et al. Does the sympathetic nervous system contribute to the pathophysiology of metabolic syndrome? Front Physiol. 2015;25(6):234.

Textor SC. Renovascular hypertension 2014: what have we learned from CORAL? J Hum Hypertens. 2015;29(3):141–2.CrossRefPubMed

Takahashi F, Goto M, Wada Y, Hasebe N. Successful treatment with an antihypertensive drug regimen including eplerenone in a patient with malignant phase hypertension with renal failure. Intern Med. 2015;54(19):2467–70.CrossRefPubMed

Kario K, Hoshide S. Age-related difference in the sleep pressure-lowering effect between an angiotensin II receptor blocker and a calcium channel blocker in Asian hypertensives: the ACS1 Study. Hypertension. 2015;65(4):729–35.CrossRefPubMed

Ferdinand KC, Nasser SA. A review of the efficacy and tolerability of combination amlodipine/valsartan in non-white patients with hypertension. Am J Cardiovasc Drugs. 2013;13(5):301–13.CrossRefPubMedPubMedCentral

10.

Singh S, Singh A, Sharma D, Singh A, Narula MK, Bhattacharjee J. Effect of l-arginine on nitric oxide levels in intrauterine growth restriction and its correlation with fetal outcome. Indian J Clin Biochem. 2015;30(3):298–304.CrossRefPubMed

11.

Shu X, Keller TC 4th, Begandt D, Butcher JT, Biwer L, Keller AS, Columbus L, Isakson BE. Endothelial nitric oxide synthase in the microcirculation. Cell Mol Life Sci. 2015;72(23):4561–75.CrossRefPubMedPubMedCentral

12.

Chakraborty S, Khan GA, Karmohapatra SK, Bhattacharya R, Bhattacharya G, Sinha AK. Purification and mechanism of action of “cortexin”, a novel antihypertensive protein hormone from kidney and its role in essential hypertension in men. J Am Soc Hypertens. 2009;3(2):119–32.CrossRefPubMed

13.

Palmer RM, Rees DD, Ashton DS, Moncada S. l-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun. 1988;153(3):1251–6.CrossRefPubMed

14.

Ghosh R, Bhattacharyya M, Khan G, Chakraborty S, Bhattacharya R, Maji UK, et al. Diagnosis of essential hypertension in humans by the determination of plasma renal cortexin using enzyme-linked immunosorbent assay. Clin Lab. 2013;59(5–6):475–81.PubMed

15.

Karmohapatra SK, Chakraborty K, Kahn NN, Sinha AK. The role of nitric oxide in aspirin induced thrombolysis in vitro and the purification of aspirin activated nitric oxide synthase from human blood platelets. Am J Hematol. 2007;82(11):986–95.CrossRefPubMed

16.

Bhattacharyya M, Karmohapatra SK, Bhattacharya G, Bhattacharya R, Sinha AK. The role of leucocytes in the acetyl salicylic acid (aspirin) induced nitric oxide synthesis in the production of interferon-alpha, a potent inhibitor of platelet aggregation and a thrombolytic agent. J Thromb Thrombolysis. 2009;28(2):173–84.CrossRefPubMed

17.

Taubert D, Berkels R, Grosser N, Schröder H, Gründemann D, Schömig E. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol. 2004;143(1):159–65 (Epub 2004 Aug 2).CrossRefPubMedPubMedCentral

18.

Monobe H, Yamanari H, Nakamura K, Ohe T. Effects of low-dose aspirin on endothelial function in hypertensive patients. Clin Cardiol. 2001;24(11):705–9.CrossRefPubMed

19.

Tlaskalová-Hogenová H, Stépánková R. Development of antibody formation in germ-free and conventionally reared rabbits: the role of intestinal lymphoid tissue in antibody formation to E. coli antigens. Folia Biol (Praha). 1980;26(2):81–93.

20.

Hoshina T, Tamura K, Kawano S, Kato T, Sato F, Horino T, et al. Two cases of Paragonimiasis westermani in a Chinese family diagnosed with the Ouchterlony double diffusion method. Kansenshogaku Zasshi. 2014;88(6):866–70.CrossRefPubMed

21.

Bockman CS, Jeffries WB, Pettinger WA, Abel PW. Reduced contractile sensitivity and vasopressin receptor affinity in DOCA-salt hypertension. Am J Physiol. 1992;262(6 Pt 2):H1752–8.PubMed

22.

Steering committee of the physicians health study research group. Final report on the aspirin component of the on going physicians health study. N. Engl. J. Med. 1989;321:129–35.CrossRef

23.

Sinha AK, Bhattacharya S, Acharya K, Mazumder S. Stimulation of nitric oxide synthesis and protective role of insulin in acute thrombosis in vivo. Life Sci. 1999;65(25):2687–96.CrossRefPubMed

24.

Engvall E, Perlmann P. Enzyme-linked immunosorbent assay, Elisa 3 Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. J Immunol. 1972;109(1):129–35.PubMed

25.

Jia L, Bonaventura C, Bonaventura J, Stamler JS. S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature. 1996;380:221–6.CrossRefPubMed

26.

Ignarro LJ, Harbison RG, Wood KS, Kadowitz PJ. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther. 1986;237:893–900.PubMed

27.

Hermida RC, Ayala DE, Mojon A, Fernandez JR. Ambulatory blood pressure control with bed time aspirin administration in subjects with prehypertension. Am J Hypertens. 2009;22(8):896–903.CrossRefPubMed

28.

Dimitrov Y, Baguet JP, Hottelart C, Marboeuf P, Tartiere JM, Ducher M, Fauvel JP. Is there a BP benefit of changing the time of aspirin administration in treated hypertensive patients? Eur J Prev Cardiol. 2012;19(4):706–11.CrossRefPubMed

29.

Antman EM, Braunwald E. Acute myocardial infarction. In: Harrison TR, Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, editors. Harrison’s principle of internal medicine. New York: McGraw-hill Inc.; 1998. p. 1352–65.

30.

Vasan RS, Larson Leip EP, Evans JC, O’Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291–7.CrossRefPubMed

31.

Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232–5.CrossRefPubMed

32.

Min YW, Song BG, Kim HS, Kim K, Lee H, Min BH, Lee JH, Son HJ, Rhee PL, Kim JJ. Associations between reflux esophagitis and the progression of coronary artery calcification: a cohort study. PLoS One. 2017;12(10):0184996.CrossRef

33.

Magen E, Viskoper JR, Mishal J, Priluk R, London D, Yosefy C. Effects of low dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. J Hum Hypertens. 2005;19(9):667–73.CrossRefPubMed

34.

Ayala DE, Hermida RC. Sex differences in the administration-time-dependent effects of low dose aspirin on ambulatory blood pressure in hypertensive subjects. Chronobiol Int. 2010;27(2):345–62.CrossRefPubMed

35.

Zanchetti A, Hansson L, Leonetti G, Rahn KH, Ruilope L, Warnold I, et al. Low dose aspirin dose not interfere with the blood pressure-lowering effects of antihypertensive therapy. J Hypertens. 2002;20(5):1015–22.CrossRefPubMed

36.

Chakraborty K, Khan GA, Banerjee P, Ray U, Sinha AK. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin. Platelets. 2003;14:421–7.CrossRefPubMed

Title: Role of Acetyl Salicylic Acid in Controlling the DOCA-Salt Induced Hypertension in Rats by Stimulating the Synthesis of r-Cortexin in the Kidney
Authors: Uttam Kumar Maji
Pradipta Jana
Mitali Chatterjee
Sanmay Karmakar
Arup Saha
Tamal Kanti Ghosh
Publication date: 01-03-2018
Publisher: Springer International Publishing
Published in: High Blood Pressure & Cardiovascular Prevention / Issue 1/2018
Print ISSN: 1120-9879
Electronic ISSN: 1179-1985
DOI: https://doi.org/10.1007/s40292-017-0241-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Role of Acetyl Salicylic Acid in Controlling the DOCA-Salt Induced Hypertension in Rats by Stimulating the Synthesis of r-Cortexin in the Kidney

Abstract

Introduction

Aim

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Aim

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Cardiac Biomarkers Release in Preadolescent Athletes After an High Intensity Exercise

Validation of Central and Peripheral Non-Invasive Hemodynamic Variables Using an Oscillometric Method

Association Between Atrial, Ventricular and Vascular Morphofunctional Alterations in Rheumatoid Arthritis

Reviewers 2017

Essential Hypertension and Functional Microvascular Ageing

Excess Body Weight, Insulin Resistance and Isolated Systolic Hypertension: Potential Pathophysiological Links